Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
Enter Symbol
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Shares Outstanding:
49M
Market Cap:
$0.15B
Avg Volume:
429403
P/E Ratio:
-0.010
PEG Ratio:
-0.010
1m
3m
6m
1y
2y
Opinion and Analysis
What Matters This Month In Biotech For AMGN, CELG, IMGN, BMRN
Feb 05, 2013 12:18 PM |
AMGN
,
CELG
,
DVAX
,
FOLD
,
ONXX
,
PFE
This Biotech Stock Is Ready To Explode
Jul 13, 2012 10:39 AM |
FOLD
FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX
Jun 22, 2009 08:19 PM |
AMGN
,
BMY
,
EURX
,
FOLD
,
MEDX
,
ONTY
More Articles on FOLD..
Press Releases
Amicus Therapeutics to Present at UBS Global Healthcare Conference
May 14, 2013 10:30 AM |
FOLD
Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013
May 02, 2013 12:40 PM |
FOLD
Amicus Therapeutics to Present at 12th Annual Needham Healthcare Conference
Apr 24, 2013 10:03 AM |
FOLD
More Press Releases on FOLD..
SEC Filings
Form 4 AMICUS THERAPEUTICS INC For: Mar 15 Filed by: Crowley John F (10K)
Mar 18, 2013 02:55 PM
Form 4 AMICUS THERAPEUTICS INC For: Mar 15 Filed by: BARER SOL J (10K)
Mar 18, 2013 02:54 PM
Form 3 AMICUS THERAPEUTICS INC For: Feb 01 Filed by: Macaluso Peter M (10K)
Feb 11, 2013 10:41 AM
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
FOLD
Compare to S&P
YTD
16.05 %
6.41 %
4 Weeks
-4.01 %
-3.91 %
12 Weeks
-14.09 %
-16.98 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
34.29 %
EPS Growth in Last Year:
-200.00 %
Sales Growth in Last Quarter:
36.83 %
Sales Growth in Last Quarter:
163.29 %
More...
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##